Table 4.
Univariate Cox model for PFS/OS for (A) entire cohort and (B) subset of PET- negative CR1 patients (B), where maintenance rituximab was modeled as a time-dependent covariate and all other variables time-independent covariates.
| A. Entire Cohort | PFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
|
|
||||
| Gender: Female vs. Male (Ref) | 0.46(0.27,0.78) | 0.004 | 0.44(0.23,0.84) | 0.013 |
| Age (year) | 1.02(1.00,1.05) | 0.074 | 1.03(1.00,1.06) | 0.054 |
| Diagnosis Year: 2006 and later vs. before 2006 (Ref) | 0.46(0.3,0.71) | <0.001 | 0.34(0.19,0.59) | <0.001 |
| B Symptoms: No vs. Yes (Ref) | 0.83(0.50,1.36) | 0.45 | 0.84(0.48,1.49) | 0.56 |
| Bone marrow involvement: No vs. Yes (Ref) | 1.07(0.66,1.73) | 0.79 | 0.94(0.53,1.69) | 0.84 |
| Extranodal involvement: No vs. Yes (Ref) | 1.26(0.82,1.94) | 0.28 | 1.43(0.85,2.42) | 0.18 |
| Blastoid variant: No vs. Yes (Ref) | 0.58(0.29,1.15) | 0.12 | 0.43(0.21,0.91) | 0.027 |
| MIPI | ||||
| Intermediate/high vs. low risk (Ref) | 1.62(0.98,2.70) | 0.061 | 1.49(0.84,2.62) | 0.17 |
| Unknown vs. low risk (Ref) | 1.47(0.87,2.47) | 0.15 | 1.02(0.56,1.88) | 0.94 |
| High-dose cytarabine pre-ASCT: No vs. Yes (Ref) | 1.56(1.05,2.32) | 0.027 | 1.59(1.00,2.54) | 0.052 |
| Rituximab pre-ASCT: No vs. Yes (Ref) | 2.16(1.22,3.82) | 0.008 | 1.69(0.87,3.27) | 0.12 |
| Regimens pre-ASCT: 2–3 vs. 1 (Ref) | 2.11(1.42,3.15) | <0.001 | 2.6(1.63,4.13) | <0.001 |
| Time from diagnosis to ASCT (month) | 1.01(1.00,1.02) | 0.069 | 1.01(1.00,1.02) | 0.17 |
| ASCT year: 2007 and later vs. before 2007 (Ref) | 0.41(0.27,0.63) | <0.001 | 0.29(0.17,0.52) | <0.001 |
| Disease status : PR1/CR2/PR2/PR3 vs. CR1 (Ref) | 2.74(1.82,4.14) | <0.001 | 3.15(1.97,5.02) | <0.001 |
| ASCT Conditioning: Radiation-based vs. Chemotherapy-only (Ref) | 0.96(0.64,1.44) | 0.85 | 0.74(0.46,1.19) | 0.21 |
| Maintenance rituximab: Yes vs. No (Ref) | 0.22 (0.13,0.37) | <0.001 | 0.14 (0.07, 0.31) | <0.001 |
| B. PET negative CR1a | PFS | OS | ||
|---|---|---|---|---|
| HR (95% CI) | P-value | HR (95% CI) | P-value | |
|
|
||||
| Gender: Female vs. Male (Ref) | 0.47(0.21,1.04) | 0.062 | 0.19(0.04,0.82) | 0.026 |
| Age (year) | 1.06(1.01,1.11) | 0.010 | 1.11(1.04,1.19) | 0.002 |
| Diagnosis Year: 2006 and later vs. before 2006 (Ref) | 0.70(0.35,1.40) | 0.31 | 0.44(0.18,1.09) | 0.076 |
| B Symptoms: No vs. Yes (Ref) | 0.45(0.20,1.00) | 0.049 | 0.58(0.19,1.75) | 0.33 |
| Bone marrow involvement: No vs. Yes (Ref) | 0.78(0.32,1.87) | 0.57 | 0.24(0.03,1.77) | 0.16 |
| Extranodal involvement: No vs. Yes (Ref) | 1.35(0.67,2.73) | 0.41 | 2.93(0.86,10.02) | 0.087 |
| Blastoid variant: No vs. Yes (Ref) | 0.41(0.14,1.16) | 0.093 | 0.28(0.08,0.98) | 0.046 |
| MIPI | ||||
| Intermediate/high vs. low risk (Ref) | 2.38(1.03,5.51) | 0.042 | 2.25(0.80,6.34) | 0.12 |
| Unknown vs. low risk (Ref) | 2.19(0.96,5.02) | 0.063 | 0.81(0.25,2.68) | 0.73 |
| High-dose cytarabine Pre-ASCT: No vs. Yes (Ref) | 2.38(1.25,4.54) | 0.009 | 2.68(1.07, 6.73) | 0.036 |
| Regimens pre-ASCT: 2–3 vs. 1 (Ref) | 1.44(0.66,3.14) | 0.36 | 2.19(0.79,6.07) | 0.13 |
| Time from diagnosis to ASCT (month) | 1.00(0.97,1.03) | 0.91 | 1.00(0.96,1.04) | 0.92 |
| ASCT year: 2007 and later vs. before 2007 (Ref) | 0.71(0.35,1.43) | 0.34 | 0.45(0.18,1.12) | 0.088 |
| ASCT Conditioning: Radiation-based vs. Chemotherapy-only (Ref) | 0.76 (0.39,1.47) | 0.41 | 0.35 (0.13,0.94) | 0.037 |
| Maintenance rituximab: Yes vs. No (Ref) | 0.22 (0.11,0.46) | <0.001 | 0.11 (0.03,0.38) | <0.001 |
Abbreviations: CR, complete remission; ASCT, high-dose therapy; MIPI, mantle cell lymphoma International prognostic index; PR, partial remission.
a
Variables excluded: disease status due to all patients being CR1; pre-HCT Rituxan due to only 1 patient being “No”.